Enterprise Value
502.1M
Cash
405.9M
Avg Qtr Burn
-28.44M
Short % of Float
9.11%
Insider Ownership
1.94%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ziftomenib) (menin inhibitor) (KO-539) Details Acute myeloid leukemia | Phase 2 Update | |
Tipifarnib Details T cell lymphoma | Phase 2 Update | |
Tipifarnib Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update | |
KO-2806 (FTI inhibitor) Details Solid tumor/s | Phase 1 Initiation |